Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-G20 in Obstructive Hypertrophic Cardiomyopathy
NCT04418297Phase 1Terminated
- Sponsor
- Celltrion
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing CT-G20 with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment-emergent adverse events at 12 days. Started Oct 2020; status: terminated.
02
Drugs
Cibenzoline S-isomer
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT04418297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418297.